{"nctId":"NCT00191386","briefTitle":"Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)","startDateStruct":{"date":"2005-05"},"conditions":["Attention Deficit Hyperactivity Disorder"],"count":228,"armGroups":[{"label":"Atomoxetine","type":"EXPERIMENTAL","interventionNames":["Drug: Atomoxetine hydrochloride"]}],"interventions":[{"name":"Atomoxetine hydrochloride","otherNames":["LY139603","Strattera"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who met all of the disease diagnostic and study criteria at Visit 2 of previous placebo-controlled study, completed the study\n* Patients wish to enter into this study\n\nExclusion Criteria:\n\n* Patients whose families anticipate a move outside the geographic range of the investigative site, or who plan extended travel inconsistent with the recommended visit interval","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events for Long Term Safety and Tolerability","description":"Details on the actual adverse events are presented in the Reported Adverse Events Section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Various Timepoints in Attention Deficit Hyperactivity Disorder Rating Scale-IV-Translated in Japanese Parent Version: Investigator Administered and Scored (ADHDRS-IV-J:I) Total Score","description":"Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.1","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"10.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Various Timepoints in the Clinical Global Impressions-Attention Deficit Hyperactivity Disorder-Severity (CGI-ADHD-S)","description":"Measures severity of the participant's overall severity of ADHD symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Cytochrome P450 2D6 (CYP2D6) Phenotype Status","description":"Participants were categorized as either extensive metabolizers (EM) or poor metabolizers (PM). CYP2D6 is the primary atomoxetine metabolizing enzyme. The CYP2D6 genotype were analysed by testing the \\*2, \\*3, \\*4, \\*5, \\*6, \\*7, \\*8, and \\*10 alleles. Metabolizer status was determined by focusing on the normal(wild type, \\*2), decreased(\\*10), and defective allele(\\*3, \\*4, \\*5, \\*6, \\*7, or \\*8). PM were assigned to the patients had two defective alleles in any combination of \\*3, \\*4, \\*5, \\*6, \\*7, or \\*8 alleles. EM was all except for PM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":228},"commonTop":["Nasopharyngitis","Headache","Influenza","Abdominal pain","Upper respiratory tract inflammation"]}}}